Aesthetic Injectables Pipeline by Development Stages, Segments, Region and Countries, Regulatory Path and Key Companies

Powered by

All the vital news, analysis, and commentary curated by our industry experts.

Aesthetic Injectables Pipeline Market Report Overview

Aesthetic injectables are gel-like substances injected beneath the skin to restore a youthful appearance by increasing the volume of sunken cheeks or temples or reducing lines around the nose and mouth, among other processes. Aesthetic Injectables are grouped into segments based on their molecular composition.

The aesthetic injectables pipeline market research report provides a comprehensive understanding of the pipeline products along with their comparative analysis at various stages of development. The report also includes information about the territories wherein the clinical trials are in progress, the regulatory paths followed by the trials, and the companies associated with the trials.

Key Segments ·       Hyaluronic Acid Fillers

·       Biphasic Hyaluronic Acid Fillers

·       Monophasic Hyaluronic Acid Fillers

·       Non-Hyaluronic Acid Fillers

·       Poly-L-Lactic Acid (PLLA) Fillers

Key Territories ·       The US

·       Europe

·       China

·       South Korea

·       Israel

Key Regulatory Paths ·       PMA

·       CE

·       NMPA

·       NIFDS

·       510(k)

Leading Companies ·       Almirall Ltd

·       Celltrix AB

·       Acro Biomedical Co Ltd

·       Advanced Aesthetic Technologies Inc.

·       Aeon Astron Corporation

Enquire & Decide Discover the perfect solution for your business needs. Enquire now and let us help you make an informed decision before making a purchase.

Aesthetic Injectables Pipeline Market Segmentation by Segments

The key segments for the aesthetic injectables pipeline market are hyaluronic acid fillers, biphasic hyaluronic acid fillers, monophasic hyaluronic acid fillers, non-hyaluronic acid fillers, and poly-l-lactic acid (PLLA) fillers. As of April 2024, hyaluronic acid fillers accounted for the highest share of pipeline products.

Hyaluronic acid (HA) is a glycosaminoglycan disaccharide that exists naturally in the body. Injections of HA are used to reduce wrinkles in the face and for soft tissue augmentation. Hyaluronic acid fillers can be further sub-segmented into biphasic hyaluronic acid fillers and monophasic hyaluronic acid fillers.

Aesthetic Injectables Pipeline Market Analysis by Segments, 2024 (%)

Aesthetic Injectables Pipeline Market Analysis by Segments, 2024 (%)

Buy the Full Report for More Segment Insights into the Aesthetic Injectables Pipeline Market

Download a Free Report Sample

Aesthetic Injectables Pipeline Market Segmentation by Territories

A few of the key territories with the aesthetic injectables pipeline market are the US, Europe, China, South Korea, and Israel. As of April 2024, the US accounted for the highest number of pipeline products.

Aesthetic Injectables Pipeline Market Analysis by Territories, 2024 (%)

Aesthetic Injectables Pipeline Market Analysis by Territories, 2024 (%)

Buy the Full Report for More Territory Insights into the Aesthetic Injectables Pipeline Market

Download a Free Report Sample

Aesthetic Injectables Pipeline Market Segmentation by Regulatory Paths

A few of the key regulatory paths in the aesthetic injectables pipeline products market are PMA, CE, NMPA, NIFDS, and 510(k). As of April 2024, PMA was the most followed pathway for pipeline products in the aesthetic injectables market.

Aesthetic Injectables Pipeline Market Analysis by Regulatory Paths, 2024 (%)

Aesthetic Injectables Pipeline Market Analysis by Regulatory Paths, 2024 (%)

Buy the Full Report for More Regulatory Path Insights into the Aesthetic Injectables Pipeline Market

Download a Free Report Sample

Aesthetic Injectables Pipeline Market – Competitive Landscape

A few of the key companies associated with the aesthetic injectables pipeline market are Almirall Ltd, Celltrix AB, Acro Biomedical Co Ltd, Advanced Aesthetic Technologies Inc., and Aeon Astron Corporation, among others.

Almirall Ltd: Almirall is headquartered in Uxbridge, Middlesex, the UK. It is a biopharmaceutical company that develops healthcare solutions for dermatology indications. The company’s product portfolio includes actikerall cutaneous solution, aknemycin plus cutaneous solution, balenum dry skin and itch relief cream, balneum cream, and other products.  

Celltrix AB: Celltrix AB is headquartered in Malmo, Sweden. It is a private biotechnology/medical device company that focuses on reconstructive cosmetic surgery. The company’s innovative product, Credurance, is produced by its unique technology, Creduranc. The benefits of Credurance include treatment for patients who desire an immediate filling effect and long-lasting as well as long-term results without using permanent implant treatment.

Aesthetic Injectables Pipeline Market Analysis by Companies, 2024

Aesthetic Injectables Pipeline Market Analysis by Companies, 2024

Buy the Full Report for More Company Insights into the Aesthetic Injectables Pipeline Market

Download a Free Report Sample

Segments Covered in the Report

Aesthetic Injectables Pipeline Market Segments Outlook (2024)

  • Hyaluronic Acid Fillers
  • Biphasic Hyaluronic Acid Fillers
  • Monophasic Hyaluronic Acid Fillers
  • Non-Hyaluronic Acid Fillers
  • Poly-L-Lactic Acid (PLLA) Fillers

Aesthetic Injectables Pipeline Market Territories Outlook (2024)

  • The US
  • Europe
  • China
  • South Korea
  • Israel

Aesthetic Injectables Pipeline Market Regulatory Paths Outlook (2024)

  • PMA
  • CE
  • NMPA
  • NIFDS
  • 510(k)

Scope

This report provides:

  • Extensive coverage of the aesthetic injectables under development.
  • Exhaustive list of major pipeline products and their details, including product description, licensing and collaboration details, and other developmental activities.
  • Reviews of major players involved in the development of aesthetic injectables and lists all their pipeline projects.
  • Coverage of pipeline products based on various stages of development ranging from early development to approved/issued stage.
  • Key clinical trial data of ongoing clinical trials specific to pipeline products.
  • Recent developments in the segment/industry.

Reasons to Buy

  • Formulate significant competitor information, analysis, and insights to improve R&D strategies.
  • Identify emerging players with potentially strong product portfolios and create effective counter strategies to gain a competitive advantage.
  • Identify and understand important and diverse types of aesthetic injectables under development.
  • Develop market-entry and market-expansion strategies.
  • Plan mergers and acquisitions effectively by identifying major players with the most promising pipeline.
  • Carry out an in-depth analysis of the product’s current stage of development, territory, and estimated launch date.

Acro Biomedical Co Ltd
Advanced Aesthetic Technologies Inc
Aeon Astron Corporation
Aesthetic Medical Device
Allergan Aesthetics
Almirall Ltd
Aquavit Pharmaceuticals Inc
Beijing MeiYan KongJian Technology Co Ltd
BioPlus Co Ltd
BioSmart Nanotechnology Ltda
Bioxis Pharmaceuticals
BMG Pharma SpA
Bmi Korea Co Ltd
CellPraxis
Celltrix AB
Collplant Biotechnologies Ltd
Croma-Pharma GmbH
Dexlevo Inc
Dongkook Pharmaceutical Co Ltd
EmulTech BV
Establishment Labs SA
Evolus Inc
Fillmed Laboratoires
G2GBIO Inc
Galderma SA
Hallura Ltd
Histogen Inc
Hugel Inc
Innova Medical Design
Innovia LLC
inSoma Bio Inc
Inventage Lab Inc
Jinwoo Bio Co Ltd
Juvenis Ltd
Khorionyx SA
KiOmed Pharma
Laboratoires Vivacy
LG Chem Ltd
LifeSprout Inc
Medytox Inc
Merz Aesthetics
Mesoestetic Pharma Group SL
Moma Therapeutics Inc
N8 Medical LLC
Oligo Medic Inc
Oxartis Ltd
PB&B SA
Peptron Inc
PetVivo Holdings Inc
Q-Med AB
Samyang Biopharmaceuticals Corp
Samyang Holdings Corp
Sebana Medical Ltd
Shanghai Haohai Biological Technology Co Ltd
Shin Poong Pharm Co Ltd
Silk Medical Aesthetics Inc
Sinclair Pharma Ltd
Sofregen Medical Inc
So-Young International Inc
Spiderwort
SunMax Biotechnology Co Ltd
SwiftPharma BV
TEI Biosciences Inc (Inactive)
Tempo Therapeutics Inc
Teoxane SA
Tetratherix Pty Ltd
Tissueform Inc
TruElastin Laboratories Inc
Trylle Skin Health Inc
University of California Santa Barbara
University of Missouri
Volumina Medical SA

Table of Contents

1 Table of Contents 3

1.1 List of Tables 7

1.2 List of Figures 15

2 Introduction 16

2.1 Aesthetic Injectables Overview 16

3 Products under Development 17

3.1 Aesthetic Injectables – Pipeline Products by Stage of Development 17

3.2 Aesthetic Injectables – Pipeline Products by Segment 18

3.3 Aesthetic Injectables – Pipeline Products by Territory 19

3.4 Aesthetic Injectables – Pipeline Products by Regulatory Path 21

3.5 Aesthetic Injectables – Pipeline Products by Estimated Approval Date 22

3.6 Aesthetic Injectables – Ongoing Clinical Trials 23

4 Aesthetic Injectables – Pipeline Products under Development by Companies 24

4.1 Aesthetic Injectables Companies – Pipeline Products by Stage of Development 24

4.2 Aesthetic Injectables – Pipeline Products by Stage of Development 27

5 Aesthetic Injectables Companies and Product Overview 31

5.1 Acro Biomedical Co Ltd Company Overview 31

5.1.1 Acro Biomedical Co Ltd Pipeline Products & Ongoing Clinical Trials Overview 31

5.2 Advanced Aesthetic Technologies Inc Company Overview 32

5.2.1 Advanced Aesthetic Technologies Inc Pipeline Products & Ongoing Clinical Trials Overview 32

5.3 Aeon Astron Corporation Company Overview 37

5.3.1 Aeon Astron Corporation Pipeline Products & Ongoing Clinical Trials Overview 37

5.4 Aesthetic Medical Device Company Overview 38

5.4.1 Aesthetic Medical Device Pipeline Products & Ongoing Clinical Trials Overview 38

5.5 Allergan Aesthetics Company Overview 41

5.5.1 Allergan Aesthetics Pipeline Products & Ongoing Clinical Trials Overview 41

5.6 Almirall Ltd Company Overview 51

5.6.1 Almirall Ltd Pipeline Products & Ongoing Clinical Trials Overview 51

5.7 Aquavit Pharmaceuticals Inc Company Overview 52

5.7.1 Aquavit Pharmaceuticals Inc Pipeline Products & Ongoing Clinical Trials Overview 52

5.8 Beijing MeiYan KongJian Technology Co Ltd Company Overview 53

5.8.1 Beijing MeiYan KongJian Technology Co Ltd Pipeline Products & Ongoing Clinical Trials Overview 53

5.9 BioPlus Co Ltd Company Overview 56

5.9.1 BioPlus Co Ltd Pipeline Products & Ongoing Clinical Trials Overview 56

5.10 BioSmart Nanotechnology Ltda Company Overview 59

5.10.1 BioSmart Nanotechnology Ltda Pipeline Products & Ongoing Clinical Trials Overview 59

5.11 Bioxis Pharmaceuticals Company Overview 60

5.11.1 Bioxis Pharmaceuticals Pipeline Products & Ongoing Clinical Trials Overview 60

5.12 BMG Pharma SpA Company Overview 63

5.12.1 BMG Pharma SpA Pipeline Products & Ongoing Clinical Trials Overview 63

5.13 Bmi Korea Co Ltd Company Overview 65

5.13.1 Bmi Korea Co Ltd Pipeline Products & Ongoing Clinical Trials Overview 65

5.14 CellPraxis Company Overview 66

5.14.1 CellPraxis Pipeline Products & Ongoing Clinical Trials Overview 66

5.15 Celltrix AB Company Overview 67

5.15.1 Celltrix AB Pipeline Products & Ongoing Clinical Trials Overview 67

5.16 Collplant Biotechnologies Ltd Company Overview 68

5.16.1 Collplant Biotechnologies Ltd Pipeline Products & Ongoing Clinical Trials Overview 68

5.17 Croma-Pharma GmbH Company Overview 70

5.17.1 Croma-Pharma GmbH Pipeline Products & Ongoing Clinical Trials Overview 70

5.18 Dexlevo Inc Company Overview 73

5.18.1 Dexlevo Inc Pipeline Products & Ongoing Clinical Trials Overview 73

5.19 Dongkook Pharmaceutical Co Ltd Company Overview 74

5.19.1 Dongkook Pharmaceutical Co Ltd Pipeline Products & Ongoing Clinical Trials Overview 74

5.20 EmulTech BV Company Overview 77

5.20.1 EmulTech BV Pipeline Products & Ongoing Clinical Trials Overview 77

5.21 Establishment Labs SA Company Overview 78

5.21.1 Establishment Labs SA Pipeline Products & Ongoing Clinical Trials Overview 78

5.22 Evolus Inc Company Overview 79

5.22.1 Evolus Inc Pipeline Products & Ongoing Clinical Trials Overview 79

5.23 Fillmed Laboratoires Company Overview 83

5.23.1 Fillmed Laboratoires Pipeline Products & Ongoing Clinical Trials Overview 83

5.24 G2GBIO Inc Company Overview 85

5.24.1 G2GBIO Inc Pipeline Products & Ongoing Clinical Trials Overview 85

5.25 Galderma SA Company Overview 86

5.25.1 Galderma SA Pipeline Products & Ongoing Clinical Trials Overview 86

5.26 Hallura Ltd Company Overview 87

5.26.1 Hallura Ltd Pipeline Products & Ongoing Clinical Trials Overview 87

5.27 Histogen Inc Company Overview 89

5.27.1 Histogen Inc Pipeline Products & Ongoing Clinical Trials Overview 89

5.28 Hugel Inc Company Overview 90

5.28.1 Hugel Inc Pipeline Products & Ongoing Clinical Trials Overview 90

5.29 Innova Medical Design Company Overview 94

5.29.1 Innova Medical Design Pipeline Products & Ongoing Clinical Trials Overview 94

5.30 Innovia LLC Company Overview 95

5.30.1 Innovia LLC Pipeline Products & Ongoing Clinical Trials Overview 95

5.31 inSoma Bio Inc Company Overview 96

5.31.1 inSoma Bio Inc Pipeline Products & Ongoing Clinical Trials Overview 96

5.32 Inventage Lab Inc Company Overview 97

5.32.1 Inventage Lab Inc Pipeline Products & Ongoing Clinical Trials Overview 97

5.33 Jinwoo Bio Co Ltd Company Overview 100

5.33.1 Jinwoo Bio Co Ltd Pipeline Products & Ongoing Clinical Trials Overview 100

5.34 Juvenis Ltd Company Overview 103

5.34.1 Juvenis Ltd Pipeline Products & Ongoing Clinical Trials Overview 103

5.35 Khorionyx SA Company Overview 104

5.35.1 Khorionyx SA Pipeline Products & Ongoing Clinical Trials Overview 104

5.36 KiOmed Pharma Company Overview 105

5.36.1 KiOmed Pharma Pipeline Products & Ongoing Clinical Trials Overview 105

5.37 Laboratoires Vivacy Company Overview 108

5.37.1 Laboratoires Vivacy Pipeline Products & Ongoing Clinical Trials Overview 108

5.38 LG Chem Ltd Company Overview 111

5.38.1 LG Chem Ltd Pipeline Products & Ongoing Clinical Trials Overview 111

5.39 LifeSprout Inc Company Overview 121

5.39.1 LifeSprout Inc Pipeline Products & Ongoing Clinical Trials Overview 121

5.40 Medytox Inc Company Overview 124

5.40.1 Medytox Inc Pipeline Products & Ongoing Clinical Trials Overview 124

5.41 Merz Aesthetics Company Overview 127

5.41.1 Merz Aesthetics Pipeline Products & Ongoing Clinical Trials Overview 127

5.42 Mesoestetic Pharma Group SL Company Overview 128

5.42.1 Mesoestetic Pharma Group SL Pipeline Products & Ongoing Clinical Trials Overview 128

5.43 Moma Therapeutics Inc Company Overview 130

5.43.1 Moma Therapeutics Inc Pipeline Products & Ongoing Clinical Trials Overview 130

5.44 N8 Medical LLC Company Overview 131

5.44.1 N8 Medical LLC Pipeline Products & Ongoing Clinical Trials Overview 131

5.45 Oligo Medic Inc Company Overview 132

5.45.1 Oligo Medic Inc Pipeline Products & Ongoing Clinical Trials Overview 132

5.46 Oxartis Ltd Company Overview 133

5.46.1 Oxartis Ltd Pipeline Products & Ongoing Clinical Trials Overview 133

5.47 PB&B SA Company Overview 134

5.47.1 PB&B SA Pipeline Products & Ongoing Clinical Trials Overview 134

5.48 Peptron Inc Company Overview 135

5.48.1 Peptron Inc Pipeline Products & Ongoing Clinical Trials Overview 135

5.49 PetVivo Holdings Inc Company Overview 136

5.49.1 PetVivo Holdings Inc Pipeline Products & Ongoing Clinical Trials Overview 136

5.50 Q-Med AB Company Overview 138

5.50.1 Q-Med AB Pipeline Products & Ongoing Clinical Trials Overview 138

5.51 Samyang Biopharmaceuticals Corp Company Overview 140

5.51.1 Samyang Biopharmaceuticals Corp Pipeline Products & Ongoing Clinical Trials Overview 140

5.52 Samyang Holdings Corp Company Overview 145

5.52.1 Samyang Holdings Corp Pipeline Products & Ongoing Clinical Trials Overview 145

5.53 Sebana Medical Ltd Company Overview 147

5.53.1 Sebana Medical Ltd Pipeline Products & Ongoing Clinical Trials Overview 147

5.54 Shanghai Haohai Biological Technology Co Ltd Company Overview 148

5.54.1 Shanghai Haohai Biological Technology Co Ltd Pipeline Products & Ongoing Clinical Trials Overview 148

5.55 Shin Poong Pharm Co Ltd Company Overview 149

5.55.1 Shin Poong Pharm Co Ltd Pipeline Products & Ongoing Clinical Trials Overview 149

5.56 Silk Medical Aesthetics Inc Company Overview 150

5.56.1 Silk Medical Aesthetics Inc Pipeline Products & Ongoing Clinical Trials Overview 150

5.57 Sinclair Pharma Ltd Company Overview 152

5.57.1 Sinclair Pharma Ltd Pipeline Products & Ongoing Clinical Trials Overview 152

5.58 Sofregen Medical Inc Company Overview 159

5.58.1 Sofregen Medical Inc Pipeline Products & Ongoing Clinical Trials Overview 159

5.59 So-Young International Inc Company Overview 160

5.59.1 So-Young International Inc Pipeline Products & Ongoing Clinical Trials Overview 160

5.60 Spiderwort Company Overview 161

5.60.1 Spiderwort Pipeline Products & Ongoing Clinical Trials Overview 161

5.61 SunMax Biotechnology Co Ltd Company Overview 162

5.61.1 SunMax Biotechnology Co Ltd Pipeline Products & Ongoing Clinical Trials Overview 162

5.62 SwiftPharma BV Company Overview 163

5.62.1 SwiftPharma BV Pipeline Products & Ongoing Clinical Trials Overview 163

5.63 TEI Biosciences Inc (Inactive) Company Overview 164

5.63.1 TEI Biosciences Inc (Inactive) Pipeline Products & Ongoing Clinical Trials Overview 164

5.64 Tempo Therapeutics Inc Company Overview 165

5.64.1 Tempo Therapeutics Inc Pipeline Products & Ongoing Clinical Trials Overview 165

5.65 Teoxane SA Company Overview 166

5.65.1 Teoxane SA Pipeline Products & Ongoing Clinical Trials Overview 166

5.66 Tetratherix Pty Ltd Company Overview 170

5.66.1 Tetratherix Pty Ltd Pipeline Products & Ongoing Clinical Trials Overview 170

5.67 Tissueform Inc Company Overview 171

5.67.1 Tissueform Inc Pipeline Products & Ongoing Clinical Trials Overview 171

5.68 TruElastin Laboratories Inc Company Overview 173

5.68.1 TruElastin Laboratories Inc Pipeline Products & Ongoing Clinical Trials Overview 173

5.69 Trylle Skin Health Inc Company Overview 174

5.69.1 Trylle Skin Health Inc Pipeline Products & Ongoing Clinical Trials Overview 174

5.70 University of California Santa Barbara Company Overview 175

5.70.1 University of California Santa Barbara Pipeline Products & Ongoing Clinical Trials Overview 175

5.71 University of Missouri Company Overview 176

5.71.1 University of Missouri Pipeline Products & Ongoing Clinical Trials Overview 176

5.72 Volumina Medical SA Company Overview 177

5.72.1 Volumina Medical SA Pipeline Products & Ongoing Clinical Trials Overview 177

6 Aesthetic Injectables- Recent Developments 180

6.1 Apr 08, 2024: CGBio Targets European Aesthetic Market, Unveils Suture ‘LUXX’ and ‘EGF Skin Booster’ for the First Time 180

6.2 Mar 25, 2024: CGBio Discovers a Breakthrough in “Cartilage” Regeneration, Demonstrates the Regenerative Capabilities of “Hyaluronic Acid Gel” for Cartilage 181

6.3 Mar 21, 2024: Allergan Aesthetics Continues to Champion Individuality, Drive Innovation and Lead with Integrity as It Hosts Expert Led Symposia at AMWC 2024 182

6.4 Mar 05, 2024: JUVEDERM VOLUMA XC For Temple Hollows Receives U.S. FDA Approval 183

6.5 Mar 05, 2024: JUVÉDERM VOLUMA XC For Temple Hollows Receives U.S. FDA Approval 184

6.6 Mar 04, 2024: Revance Therapeutics Announces Proposed $100M Share Offering 186

6.7 Mar 01, 2024: Evolus Announces Results from European Head-to-Head Filler Trial 186

6.8 Feb 27, 2024: Anika to Issue Fourth Quarter and Year-End 2023 Financial Results on Wednesday, March 13, 2024 186

6.9 Feb 27, 2024: LG Chem to Raise 1 tln Won in Bond Sale 187

6.10 Feb 22, 2024: AbbVie Selling $15 Billion Bonds to Buy ImmunoGen, Cerevel 187

6.11 Feb 07, 2024: Galderma Launches ‘Next’, a Ground-Breaking Trend Report That Unveils the Future of Aesthetics 187

6.12 Feb 05, 2024: AbbVie’s Full Year 2023 Sees

6.4% Net Revenue Drop 188

6.13 Feb 02, 2024: Galderma Celebrates 25 Years of Excellence in Biostimulation With Sculptra at the 2024 IMCAS 188

6.14 Jan 22, 2024: Galderma Announces Regulatory Approval for Restylane SHAYPE, a new Hyaluronic Acid Injectable Designed for Augmenting the Chin Region 189

6.15 Jan 04, 2024: AbbVie to Host Full-Year and Fourth-Quarter 2023 Earnings Conference Call 190

6.16 Jan 03, 2024: Medytox Announces Executive Appointments in Luvantas, Inc 190

6.17 Nov 01, 2023: CollPlant Biotechnologies Announces Patent Granted in U.S. for Photocurable Dermal Filler 190

6.18 Oct 31, 2023: SKINVIVE by JUVEDERM Now Available from Dermatologist Dr. Ellen Turner 190

6.19 Oct 31, 2023: LG Chem Announces 3Q Management Performance 191

6.20 Oct 10, 2023: Anika to Issue Third Quarter 2023 Financial Results on Thursday, November 2, 2023 192

6.21 Oct 04, 2023: AbbVie to Host Third-Quarter 2023 Earnings Conference Call 192

6.22 Sep 28, 2023: Merz Aesthetics Continues to Fuel Confidence by Expanding Belotero Balance (+) Filler Treatment Areas 192

6.23 Sep 19, 2023: Revance Provides Corporate Update at Investor Day 193

6.24 Sep 01, 2023: Shanghai Haohai Biological Technology Co. Announces Interim Report 2023 194

6.25 Aug 24, 2023: CollPlant Biotechnologies Announces Second Quarter Financial Results For 2023 with Revenues of $10.2 Million 195

6.26 Aug 10, 2023: Medytox Appoints Director Kim Jae-wook to Oversee Medical Division 198

6.27 Aug 01, 2023: Allergan Aesthetics Announces First Ever JUVEDERM Day 198

6.28 Jun 26, 2023: Collplant Achieves Milestone and to Receive $10 Million From Abbvie in Accordance With Its Regenerative Dermal Filler Product Collaboration Agreement 199

6.29 Jun 12, 2023: Croma-Pharma announces enrollment of first patient in hyaluronic acid dermal filler clinical trial in China 200

6.30 May 30, 2023: Establishment labs announces CE mark approval for minimally invasive surgical tools 200

6.31 May 25, 2023: Samyang Holdings to supply 100 billion worth of its filler to China 201

6.32 May 15, 2023: SKINVIVE by JUVÉDERM receives U.S. FDA approval 201

7 Appendix 203

7.1 Methodology 203

7.2 About GlobalData 206

7.3 Contact Us 206

7.4 Disclaimer 206

Table

Aesthetic Injectables – Pipeline Products by Stage of Development 17

Aesthetic Injectables – Pipeline Products by Segment 18

Aesthetic Injectables – Pipeline Products by Territory 19

Aesthetic Injectables – Pipeline Products by Regulatory Path 21

Aesthetic Injectables – Pipeline Products by Estimated Approval Date 22

Aesthetic Injectables – Ongoing Clinical Trials 23

Aesthetic Injectables Companies – Pipeline Products by Stage of Development 24

Aesthetic Injectables – Pipeline Products by Stage of Development 27

Acro Biomedical Co Ltd Pipeline Products & Ongoing Clinical Trials Overview 31

ACROFILL – Product Status 31

ACROFILL – Product Description 31

Advanced Aesthetic Technologies Inc Pipeline Products & Ongoing Clinical Trials Overview 32

Algeness DF – Product Status 32

Algeness DF – Product Description 32

Algeness HD – Product Status 33

Algeness HD – Product Description 33

Algeness LD – Product Status 33

Algeness LD – Product Description 34

Algeness VL – Product Status 34

Algeness VL – Product Description 34

Advanced Aesthetic Technologies Inc – Ongoing Clinical Trials Overview 35

Algeness VL – A Pivotal Clinical Study to Evaluate the Effectiveness and Safety of Algeness VL for the Correction of Moderate to Severe Nasolabial Folds 36

Algeness VL – A Prospective, Multi-center, Randomized, Controlled, Single-blind Study of the Safety and Effectiveness of Algeness DF 3.5% Deep Volumizing Filler to Correct Age-related Volume Deficit in the Mid-face 36

Aeon Astron Corporation Pipeline Products & Ongoing Clinical Trials Overview 37

BioDermal Filler – Product Status 37

BioDermal Filler – Product Description 37

Aesthetic Medical Device Pipeline Products & Ongoing Clinical Trials Overview 38

Alluris – Product Status 38

Alluris – Product Description 38

Skinlumina – Product Status 39

Skinlumina – Product Description 39

SkinTechMD – Product Status 39

SkinTechMD – Product Description 40

Allergan Aesthetics Pipeline Products & Ongoing Clinical Trials Overview 41

AAM SubQ Body Filler – Product Status 41

AAM SubQ Body Filler – Product Description 42

ADM Subdermal Body Filler – Product Status 42

ADM Subdermal Body Filler – Product Description 42

Elastagen – Acne Scars – Product Status 42

Elastagen – Acne Scars – Product Description 43

Elastagen – Skin Quality – Product Status 43

Elastagen – Skin Quality – Product Description 43

HA Threads – Product Status 43

HA Threads – Product Description 44

Juvederm – Decolletage – Product Status 44

Juvederm – Decolletage – Product Description 44

Juvederm – Hands – Product Status 44

Juvederm – Hands – Product Description 45

Juvederm – Neck Lines – Product Status 45

Juvederm – Neck Lines – Product Description 45

Juvederm RejuveCross – Deep Wrinkles – Product Status 45

Juvederm RejuveCross – Deep Wrinkles – Product Description 46

Juvederm RejuveCross – Etched Lines Wrinkles – Product Status 46

Juvederm RejuveCross – Etched Lines Wrinkles – Product Description 46

Juvederm RejuveCross Volumize – Cheek Augmentation – Product Status 46

Juvederm RejuveCross Volumize – Cheek Augmentation – Product Description 47

Juvederm Voluma – Nose – Product Status 47

Juvederm Voluma – Nose – Product Description 47

Juvederm Voluma Global – Malar Augmentation – Product Status 47

Juvederm Voluma Global – Malar Augmentation – Product Description 48

JUVEDERM VOLUMA XC – Temple Augmentation – Product Status 48

JUVEDERM VOLUMA XC – Temple Augmentation – Product Description 48

Allergan Aesthetics – Ongoing Clinical Trials Overview 49

Juvederm Voluma Global – Malar Augmentation – Clinical, Instrumental and Histological Evaluation of the Combined Use of Onabotulinumtoxin A and Hyaluronic Acid Fillers in Patients with Facial Paralysis 50

Almirall Ltd Pipeline Products & Ongoing Clinical Trials Overview 51

Hyaluronic Acid Facial Filler – Product Status 51

Hyaluronic Acid Facial Filler – Product Description 51

Aquavit Pharmaceuticals Inc Pipeline Products & Ongoing Clinical Trials Overview 52

Aquabelo – Product Status 52

Aquabelo – Product Description 52

Beijing MeiYan KongJian Technology Co Ltd Pipeline Products & Ongoing Clinical Trials Overview 53

Complex Collagen Filler (Type III) – Product Status 53

Complex Collagen Filler (Type III) – Product Description 53

First Generation PLLA Filler (Type III) – Product Status 54

First Generation PLLA Filler (Type III) – Product Description 54

Second Generation PCL Filler (Type III) – Product Status 54

Second Generation PCL Filler (Type III) – Product Description 55

BioPlus Co Ltd Pipeline Products & Ongoing Clinical Trials Overview 56

HyalDew All – Product Status 56

HyalDew All – Product Description 56

HyalDew Fine – Product Status 57

HyalDew Fine – Product Description 57

HyalDew Shine – Product Status 57

HyalDew Shine – Product Description 58

HyalDew-Mid – Product Status 58

HyalDew-Mid – Product Description 58

BioSmart Nanotechnology Ltda Pipeline Products & Ongoing Clinical Trials Overview 59

Hyaluronic Acid Dermal Filler – Product Status 59

Hyaluronic Acid Dermal Filler – Product Description 59

Bioxis Pharmaceuticals Pipeline Products & Ongoing Clinical Trials Overview 60

Cytosmile – Product Status 60

Cytosmile – Product Description 60

MTI-12 – Product Status 61

MTI-12 – Product Description 61

MTI-12 – Surgical Repair – Product Status 61

MTI-12 – Surgical Repair – Product Description 62

BMG Pharma SpA Pipeline Products & Ongoing Clinical Trials Overview 63

SGA300 – Product Status 63

SGA300 – Product Description 63

SGA302 – Product Status 64

SGA302 – Product Description 64

Bmi Korea Co Ltd Pipeline Products & Ongoing Clinical Trials Overview 65

BMI4002 – Product Status 65

BMI4002 – Product Description 65

CellPraxis Pipeline Products & Ongoing Clinical Trials Overview 66

Lipage – Product Status 66

Lipage – Product Description 66

Celltrix AB Pipeline Products & Ongoing Clinical Trials Overview 67

Credurance – Product Status 67

Credurance – Product Description 67

Collplant Biotechnologies Ltd Pipeline Products & Ongoing Clinical Trials Overview 68

rhCollagen Based Photocurable Regenerative Dermal Filler – Product Status 68

rhCollagen Based Photocurable Regenerative Dermal Filler – Product Description 68

rhCollagen Based Soft Tissue Filler – Product Status 69

rhCollagen Based Soft Tissue Filler – Product Description 69

Croma-Pharma GmbH Pipeline Products & Ongoing Clinical Trials Overview 70

Saypha Volume Plus Lidocaine – Product Status 70

Saypha Volume Plus Lidocaine – Product Description 70

Croma-Pharma GmbH – Ongoing Clinical Trials Overview 71

Saypha Volume Plus Lidocaine – A Randomized, Multi-center, Evaluator-blinded, Parallel Assignment, Active Controlled Study to Evaluate the Efficacy and Safety of Princess Voluma plus and Restylane Perlane Lidocaine for Correction of Midface Volume Deficit And/Or Midface Contour Deficiency 72

Dexlevo Inc Pipeline Products & Ongoing Clinical Trials Overview 73

Gouri – Product Status 73

Gouri – Product Description 73

Dongkook Pharmaceutical Co Ltd Pipeline Products & Ongoing Clinical Trials Overview 74

DKB-119 – Product Status 74

DKB-119 – Product Description 74

DKB-133 – Product Status 75

DKB-133 – Product Description 75

DKM-410 – Product Status 75

DKM-410 – Product Description 76

DKM-423 – Product Status 76

DKM-423 – Product Description 76

EmulTech BV Pipeline Products & Ongoing Clinical Trials Overview 77

SC Injectable Collagen Stimulator – Product Status 77

SC Injectable Collagen Stimulator – Product Description 77

Establishment Labs SA Pipeline Products & Ongoing Clinical Trials Overview 78

Motiva Injector – Product Status 78

Motiva Injector – Product Description 78

Evolus Inc Pipeline Products & Ongoing Clinical Trials Overview 79

Evolysse Eye Infraorbital Hollows Filler – Product Status 79

Evolysse Eye Infraorbital Hollows Filler – Product Description 80

Evolysse Lift Nasolabial Folds Filler – Product Status 80

Evolysse Lift Nasolabial Folds Filler – Product Description 80

Evolysse Lips Volumizing And Countering Filler – Product Status 81

Evolysse Lips Volumizing And Countering Filler – Product Description 81

Evolysse Sculpt Mid Face Volume Filler – Product Status 81

Evolysse Sculpt Mid Face Volume Filler – Product Description 82

Evolysse Smooth Nasolabial Folds Filler – Product Status 82

Evolysse Smooth Nasolabial Folds Filler – Product Description 82

Fillmed Laboratoires Pipeline Products & Ongoing Clinical Trials Overview 83

NCTF 135 – Product Status 83

NCTF 135 – Product Description 83

NCTF 135 HA – Product Status 84

NCTF 135 HA – Product Description 84

G2GBIO Inc Pipeline Products & Ongoing Clinical Trials Overview 85

GB-3001 – Product Status 85

GB-3001 – Product Description 85

Galderma SA Pipeline Products & Ongoing Clinical Trials Overview 86

Biostimulator Filler – Product Status 86

Biostimulator Filler – Product Description 86

Hallura Ltd Pipeline Products & Ongoing Clinical Trials Overview 87

BiOLinkMatrix Gel – Product Status 87

BiOLinkMatrix Gel – Product Description 87

Hyaluronic Acid Dermal Filler – Product Status 88

Hyaluronic Acid Dermal Filler – Product Description 88

Histogen Inc Pipeline Products & Ongoing Clinical Trials Overview 89

HST002 – Product Status 89

HST002 – Product Description 89

Hugel Inc Pipeline Products & Ongoing Clinical Trials Overview 90

The Chaeum Pure No.1 – Product Status 90

The Chaeum Pure No.1 – Product Description 91

The Chaeum Pure No.2 – Product Status 91

The Chaeum Pure No.2 – Product Description 91

The Chaeum Pure No.3 – Product Status 92

The Chaeum Pure No.3 – Product Description 92

The Chaeum Pure No.4 – Product Status 92

The Chaeum Pure No.4 – Product Description 93

The Chaeum Style – Product Status 93

The Chaeum Style – Product Description 93

Innova Medical Design Pipeline Products & Ongoing Clinical Trials Overview 94

Aesthetic Injection – Product Status 94

Aesthetic Injection – Product Description 94

Innovia LLC Pipeline Products & Ongoing Clinical Trials Overview 95

Wrinkle Filler – Product Status 95

Wrinkle Filler – Product Description 95

inSoma Bio Inc Pipeline Products & Ongoing Clinical Trials Overview 96

Fractomer – Product Status 96

Fractomer – Product Description 96

Inventage Lab Inc Pipeline Products & Ongoing Clinical Trials Overview 97

IVL-MD-B001 – Product Status 97

IVL-MD-B001 – Product Description 97

IVL-MD-F001 – Product Status 98

IVL-MD-F001 – Product Description 98

IVL-MD-F002 – Product Status 98

IVL-MD-F002 – Product Description 99

Jinwoo Bio Co Ltd Pipeline Products & Ongoing Clinical Trials Overview 100

HA Filler – Product Status 100

HA Filler – Product Description 100

HA Thread Filler – Product Status 101

HA Thread Filler – Product Description 101

Wool Filler – Product Status 102

Wool Filler – Product Description 102

Juvenis Ltd Pipeline Products & Ongoing Clinical Trials Overview 103

Tenergel – Product Status 103

Tenergel – Product Description 103

Khorionyx SA Pipeline Products & Ongoing Clinical Trials Overview 104

Autologous Globin Dermal Filler – Product Status 104

Autologous Globin Dermal Filler – Product Description 104

KiOmed Pharma Pipeline Products & Ongoing Clinical Trials Overview 105

KIO015 Intradermal Injectable Device – Product Status 105

KIO015 Intradermal Injectable Device – Product Description 105

KiOmed Pharma – Ongoing Clinical Trials Overview 106

KIO015 Intradermal Injectable Device – A Randomized, Controlled, Split-Face Study to Evaluate the Clinical Performance and Safety of KIO015 for Improving Face Skin Hydration 107

Laboratoires Vivacy Pipeline Products & Ongoing Clinical Trials Overview 108

IPN-21-SENSE Dermal Filler – Product Status 108

IPN-21-SENSE Dermal Filler – Product Description 108

Laboratoires Vivacy – Ongoing Clinical Trials Overview 109

IPN-21-SENSE Dermal Filler – A Multicenter, Prospective, Randomized Controlled Clinical Study of IPN-21-SENSE, a Novel Hyaluronic Acid Based Gel for Volume Deficiency in the Mid-face 110

LG Chem Ltd Pipeline Products & Ongoing Clinical Trials Overview 111

Dermal Filler (LR19059) – Product Status 111

Dermal Filler (LR19059) – Product Description 112

Dermal Filler (LR19093) – Product Status 112

Dermal Filler (LR19093) – Product Description 112

Hyaluronic Acid Filler (LR19094) – Product Status 112

Hyaluronic Acid Filler (LR19094) – Product Description 113

Hyaluronic Acid Filler (LR20023) – Product Status 113

Hyaluronic Acid Filler (LR20023) – Product Description 113

Hyaluronic Acid Filler (LR20024) – Product Status 114

Hyaluronic Acid Filler (LR20024) – Product Description 114

Next Generation Hyaluronic Acid Filler (LR20008) – Product Status 114

Next Generation Hyaluronic Acid Filler (LR20008) – Product Description 115

YVOIRE Y-Solution 360 – Product Status 115

YVOIRE Y-Solution 360 – Product Description 115

YVOIRE Y-Solution 540 – Product Status 116

YVOIRE Y-Solution 540 – Product Description 116

YVOIRE Y-Solution 720 – Product Status 116

YVOIRE Y-Solution 720 – Product Description 117

LG Chem Ltd – Ongoing Clinical Trials Overview 118

YVOIRE Y-Solution 360 – A Multicenter, Randomized, Rater-Blinded, No-Treatment Control Design Clinical Investigation to Evaluate the Effectiveness and Safety of YVOIRE Y-Solution 360 for Lip Augmentation 119

YVOIRE Y-Solution 540 – A Randomized, Multicenter, Evaluator-blinded, Active-controlled, Parallel-group Design Investigation to Evaluate the Effectiveness and Safety of YVOIRE Y-Solution 540 Versus YVOIRE Volume Plus in Nasolabial Folds Injection 120

LifeSprout Inc Pipeline Products & Ongoing Clinical Trials Overview 121

Lumina – Product Status 121

Lumina – Product Description 121

LifeSprout Inc – Ongoing Clinical Trials Overview 122

Lumina – A Prospective, Randomized, Controlled, Multi-center Study of the Safety and Effectiveness of Lumina in the Treatment of Nasolabial Folds 123

Medytox Inc Pipeline Products & Ongoing Clinical Trials Overview 124

MT943 – Product Status 124

MT943 – Product Description 124

Neuramis Deep Lidocaine – Product Status 125

Neuramis Deep Lidocaine – Product Description 125

Neuramis Volume Lidocaine – Product Status 125

Neuramis Volume Lidocaine – Product Description 126

Merz Aesthetics Pipeline Products & Ongoing Clinical Trials Overview 127

VP1 Lido US – Product Status 127

VP1 Lido US – Product Description 127

Mesoestetic Pharma Group SL Pipeline Products & Ongoing Clinical Trials Overview 128

LIFT001 – Product Status 128

LIFT001 – Product Description 128

mRDX-02-17 – Product Status 129

mRDX-02-17 – Product Description 129

Moma Therapeutics Inc Pipeline Products & Ongoing Clinical Trials Overview 130

Restogel – 131 – Product Status 130

Restogel – 131 – Product Description 130

N8 Medical LLC Pipeline Products & Ongoing Clinical Trials Overview 131

Ceragenin-Infused Dermal Filler – Product Status 131

Ceragenin-Infused Dermal Filler – Product Description 131

Oligo Medic Inc Pipeline Products & Ongoing Clinical Trials Overview 132

AntaRep – Product Status 132

AntaRep – Product Description 132

Oxartis Ltd Pipeline Products & Ongoing Clinical Trials Overview 133

Intra-Dermal Filler – Product Status 133

Intra-Dermal Filler – Product Description 133

PB&B SA Pipeline Products & Ongoing Clinical Trials Overview 134

PB&B Facial Volumizer – Product Status 134

PB&B Facial Volumizer – Product Description 134

Peptron Inc Pipeline Products & Ongoing Clinical Trials Overview 135

PLA Dermal Filler – Product Status 135

PLA Dermal Filler – Product Description 135

PetVivo Holdings Inc Pipeline Products & Ongoing Clinical Trials Overview 136

CosmetaLife – Product Status 136

CosmetaLife – Product Description 136

Dermal Filler – Lip – Product Status 137

Dermal Filler – Lip – Product Description 137

Q-Med AB Pipeline Products & Ongoing Clinical Trials Overview 138

GAL1906 – Product Status 138

GAL1906 – Product Description 138

GP0112 – Product Status 139

GP0112 – Product Description 139

Samyang Biopharmaceuticals Corp Pipeline Products & Ongoing Clinical Trials Overview 140

Aesthetic Filler – Product Status 140

Aesthetic Filler – Product Description 140

Lafullen Dermal Filler – Product Status 141

Lafullen Dermal Filler – Product Description 141

SYB Filler (SF-01) – Product Status 141

SYB Filler (SF-01) – Product Description 142

Samyang Biopharmaceuticals Corp – Ongoing Clinical Trials Overview 143

Lafullen Dermal Filler – A Randomized, Evaluator-blind, Matched Pairs, Prospective, Non Inferiority, Confirmatory Study to Compare the Safety and Efficacy Between Lafullen15 and Lafullen in the Correction of Nasolabial Folds 144

Samyang Holdings Corp Pipeline Products & Ongoing Clinical Trials Overview 145

SYM-1912 – Product Status 145

SYM-1912 – Product Description 145

SYM-2005 – Product Status 146

SYM-2005 – Product Description 146

SYM-2303 – Product Status 146

SYM-2303 – Product Description 146

Sebana Medical Ltd Pipeline Products & Ongoing Clinical Trials Overview 147

Dermal Filler – Product Status 147

Dermal Filler – Product Description 147

Shanghai Haohai Biological Technology Co Ltd Pipeline Products & Ongoing Clinical Trials Overview 148

Organic Cross-Linked HA Dermal Filler – Product Status 148

Organic Cross-Linked HA Dermal Filler – Product Description 148

Shin Poong Pharm Co Ltd Pipeline Products & Ongoing Clinical Trials Overview 149

FreeWink – Product Status 149

FreeWink – Product Description 149

Silk Medical Aesthetics Inc Pipeline Products & Ongoing Clinical Trials Overview 150

Dermal Filler – Product Status 150

Dermal Filler – Product Description 150

SMA-001 – Product Status 151

SMA-001 – Product Description 151

Sinclair Pharma Ltd Pipeline Products & Ongoing Clinical Trials Overview 152

Atlean – Product Status 152

Atlean – Product Description 152

Ellanse Lidocaine – Product Status 153

Ellanse Lidocaine – Product Description 153

MaiLi – Product Status 153

MaiLi – Product Description 154

MaiLi Extreme – Product Status 154

MaiLi Extreme – Product Description 154

Perfectha G – Product Status 155

Perfectha G – Product Description 155

Sinclair Pharma Ltd – Ongoing Clinical Trials Overview 156

Ellanse Lidocaine – Prospective, Single Site, Controlled Comparative Study to Identify and Assess Tissue Responses After Injection With Various Biostimulatory Products 157

MaiLi Extreme – A Post Market Clinical Follow Up (PMCF) Study to Assess the Safety and Efficacy of MaiLi Volume and MaiLi Extreme in the Treatment of Temporal Hollowing, Mid-Face Volume Deficit, Jawline Ptosis, and Chin Retrusion 158

Sofregen Medical Inc Pipeline Products & Ongoing Clinical Trials Overview 159

Silk Protein – Tissue/Dermal Filler – Product Status 159

Silk Protein – Tissue/Dermal Filler – Product Description 159

So-Young International Inc Pipeline Products & Ongoing Clinical Trials Overview 160

Extracellular Matrix Bio Gel Injectable Filler – Product Status 160

Extracellular Matrix Bio Gel Injectable Filler – Product Description 160

Spiderwort Pipeline Products & Ongoing Clinical Trials Overview 161

CelluJuve – Product Status 161

CelluJuve – Product Description 161

SunMax Biotechnology Co Ltd Pipeline Products & Ongoing Clinical Trials Overview 162

Sunmax FULLSGEN With Lidocaine – Product Status 162

Sunmax FULLSGEN With Lidocaine – Product Description 162

SwiftPharma BV Pipeline Products & Ongoing Clinical Trials Overview 163

Injectable Dermal Filler – Product Status 163

Injectable Dermal Filler – Product Description 163

TEI Biosciences Inc (Inactive) Pipeline Products & Ongoing Clinical Trials Overview 164

Injectable Dermal Filler – Product Status 164

Injectable Dermal Filler – Product Description 164

Tempo Therapeutics Inc Pipeline Products & Ongoing Clinical Trials Overview 165

MAP Tissue Scaffold-Based Dermal Filler – Product Status 165

MAP Tissue Scaffold-Based Dermal Filler – Product Description 165

Teoxane SA Pipeline Products & Ongoing Clinical Trials Overview 166

Next Generation Dermal Filler – Product Status 166

Next Generation Dermal Filler – Product Description 166

Teosyal RHA 1 – Product Status 167

Teosyal RHA 1 – Product Description 167

Teoxane SA – Ongoing Clinical Trials Overview 168

Teosyal RHA 1 – A Prospective, Single Blind, Single-center Study Evaluating the Histology and Intradermal Implantation of the Teosyal RHA Collection of Fillers 169

Tetratherix Pty Ltd Pipeline Products & Ongoing Clinical Trials Overview 170

Tetrafill – Product Status 170

Tetrafill – Product Description 170

Tissueform Inc Pipeline Products & Ongoing Clinical Trials Overview 171

NatruDerme – Product Status 171

NatruDerme – Product Description 171

PureVoluma – Product Status 172

PureVoluma – Product Description 172

TruElastin Laboratories Inc Pipeline Products & Ongoing Clinical Trials Overview 173

TEL219 – Product Status 173

TEL219 – Product Description 173

Trylle Skin Health Inc Pipeline Products & Ongoing Clinical Trials Overview 174

Collagen-Based Dermal Filler – Product Status 174

Collagen-Based Dermal Filler – Product Description 174

University of California Santa Barbara Pipeline Products & Ongoing Clinical Trials Overview 175

Needle Free Injector – Product Status 175

Needle Free Injector – Product Description 175

University of Missouri Pipeline Products & Ongoing Clinical Trials Overview 176

Collagen-Based Dermal Filler – Product Status 176

Collagen-Based Dermal Filler – Product Description 176

Volumina Medical SA Pipeline Products & Ongoing Clinical Trials Overview 177

Adipearl – Product Status 177

Adipearl – Product Description 177

Volumina Medical SA – Ongoing Clinical Trials Overview 178

Adipearl – A Single-Arm Pilot Study to Evaluate the Safety of Adipearl Injection in the Subcutaneous Tissues of Adults 179

Adipearl – A Single-Arm, Prospective, Clinical Investigation Evaluating the Safety and Feasibility of Adipearl Implantation in the Face of Adult Subjects 179

Glossary 205

Figures

Aesthetic Injectables – Pipeline Products by Stage of Development 17

Aesthetic Injectables – Pipeline Products by Segment 18

Aesthetic Injectables – Pipeline Products by Territory 19

Aesthetic Injectables – Pipeline Products by Regulatory Path 21

Aesthetic Injectables – Pipeline Products by Estimated Approval Date 22

Aesthetic Injectables – Ongoing Clinical Trials 23

Frequently asked questions

Aesthetic Injectables Pipeline by Development Stages, Segments, Region and Countries, Regulatory Path and Key Companies standard reports
Currency USD
$4,000

Can be used by individual purchaser only

$12,000

Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company


Undecided about purchasing this report?

Enquire Before Buying Request a Free Sample

Get in touch to find out about multi-purchase discounts

reportstore@globaldata.com
Tel +44 20 7947 2745

Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.

Sample Report

Aesthetic Injectables Pipeline by Development Stages, Segments, Region and Countries, Regulatory Path and Key Companies was curated by the best experts in the industry and we are confident about its unique quality. However, we want you to make the most beneficial decision for your business, so we offer free sample pages to help you:

  • Assess the relevance of the report
  • Evaluate the quality of the report
  • Justify the cost

Download your copy of the sample report and make an informed decision about whether the full report will provide you with the insights and information you need.

Below is a sample report to understand what you are buying

See what our customers are saying
testimonial-image
testimonial-image
testimonial-image
testimonial-image
testimonial-image
testimonial-image
testimonial-image

“The GlobalData platform is our go-to tool for intelligence services. GlobalData provides an easy way to access comprehensive intelligence data around multiple sectors, which essentially makes it a one-for-all intelligence platform, for tendering and approaching customers.

GlobalData is very customer orientated, with a high degree of personalised services, which benefits everyday use. The highly detailed project intelligence and forecast reports can be utilised across multiple departments and workflow scopes, from operational to strategic level, and often support strategic decisions. GlobalData Analytics and visualisation solutions has contributed positively when preparing management presentations and strategic papers.”

Business Intelligence & Marketing Manager, SAL Heavy Lift

“COVID-19 has caused significant interference to our business and the COVID-19 intelligence from GlobalData has helped us reach better decisions around strategy. These two highlights have helped enormously to understand the projections into the future concerning our business units, we also utilise the project database to source new projects for Liebherr-Werk to use as an additional source to pitch for new business.”

Market Analyst & Management, Liebherr-Werk

Your daily news has saved me a lot of time and keeps me up-to-date with what is happening in the market, I like that you almost always have a link to the source origin. We also use your market data in our Strategic Business Process to support our business decisions. By having everything in one place on the Intelligence Center it has saved me a lot of time versus looking on different sources, the alert function also helps with this.

Head of Key Accounts, Saab AB

Having used several other market research companies, I find that GlobalData manages to provide that ‘difficult-to-get’ market data that others can’t, as well as very diverse and complete consumer surveys.

Marketing Intelligence Manager, Portugal Foods

Our experience with GlobalData has been very good, from the platform itself to the people. I find that the analysts and the account team have a high level of customer focus and responsiveness and therefore I can always rely on. The platform is more holistic than other providers. It is convenient and almost like a one stop shop. The pricing suite is highly competitive and value for our organisation.

I like reports that inform new segments such as the analysis on generation Z, millennials, the impact of COVID 19 to our banking customers and their new channel habits. Secondly the specialist insight on affluent sector significantly increases our understanding about this group of customers. The combination of those give us depth and breadth of the evolving market.

I’m in the business of answering and helping people make decisions so with the intelligence center I can do that, effectively and efficiently. I can share quickly key insights that answer and satisfy our country stakeholders by giving them many quality studies and primary research about competitive landscape beyond the outlook of our bank. It helps me be seen as an advisory partner and that makes a big difference. A big benefit of our subscription is that no one holds the whole data and because it allows so many people, so many different parts of our organisation have access, it enables all teams to have the same level of knowledge and decision support.

Head of Customer Insight and Research, Standard Chartered

“I know that I can always rely on Globaldata’s work when I’m searching for the right consumer and market insights. I use Globaldata insights to understand the changing market & consumer landscape and help create better taste & wellbeing solutions for our customers in food, beverage and healthcare industries.

Globaldata has the right data and the reports are of very high quality compared to your competitors. Globaldata not only has overall market sizes & consumer insights on food & beverages but also provides insights at the ingredient & flavour level. That is key for B2B companies like Givaudan. This way we understand our customers’ business and also gain insight to our unique industry”

Head of Consumer Sensory Insights, Givaudan

GlobalData provides a great range of information and reports on various sectors that is highly relevant, timely, easy to access and utilise.  The reports and data dashboards help engagement with clients; they provide valuable industry and market insights that can enrich client conversations and can help in the shaping of value propositions. Moreover, using GlobalData products has helped increase my knowledge of the finance sector, the players within it, and the general threats and opportunities.

I find the consumer surveys that are carried out to be extremely beneficial and not something I have seen anywhere else. They provided an insightful view of why and which consumers take (or don’t) particular financial products. This can help shape conversations with clients to ensure they make the right strategic decisions for their business.

One of the challenges I have found is that data in the payments space is often piecemeal. With GD all of the data I need is in one place, but it also comes with additional market reports that provide useful extra context and information. Having the ability to set-up alerts on relevant movements in the industry, be it competitors or customers, and have them emailed directly to me, ensures I get early sight of industry activity and don’t have to search for news.

Senior Account Manager, TSYS
Go even deeper with GlobalData Intelligence Center

Every Company Report we produce is powered by the GlobalData Intelligence Center.

Subscribing to our intelligence platform means you can monitor developments at Aesthetic Injectables Pipeline by Development Stages, Segments, Region and Countries, Regulatory Path and Key Companies in real time.

  • Access a live Aesthetic Injectables Pipeline by Development Stages, Segments, Region and Countries, Regulatory Path and Key Companies dashboard for 12 months, with up-to-the-minute insights.
  • Fuel your decision making with real-time deal coverage and media activity.
  • Turn insights on financials, deals, products and pipelines into powerful agents of commercial advantage.